NCT01186458TerminatedPhase 2
A Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma: Hoosier Oncology Group LYM08-134
Hoosier Cancer Research Network11 sites in 1 country4 target enrollmentStarted: October 2010Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Enrollment
- 4
- Locations
- 11
- Primary Endpoint
- Overall Response Rate
Study Overview
Brief Summary
The purpose of this study is to determine the effectiveness of fludarabine, Velcade, and rituximab treatment regimen in patients with relapsed or refractory follicular non-Hodgkin lymphoma.
Detailed Description
OUTLINE: This is a multi-center study.
- Fludarabine 25 mg/m2 IV over 30 minutes , Days 1, 2, 4
- Velcade(given after fludarabine) 1.3 mg/m2 IV push over 3 to 5 seconds, Days 1, 4, 8, 11
- Rituximab (given after Velcade) 375 mg/m2 IV piggyback, Day 1
- Cycle = 28 days; max 6 cycles
ECOG Performance Status: 0-2
Life Expectancy: Not specified
Hematopoietic:
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Must have histologically confirmed Follicular Non-Hodgkin Lymphoma (Grade I, II, or IIIa)
- •Must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded as ≥2 cm with conventional techniques or as >1 cm with spiral CT scan) and obtained by imaging within 30 days prior to registration for protocol therapy.
- •Must have received at least one prior therapeutic regimen, but no more than three prior regimens of conventional cytotoxic therapy. NOTE: Prior recipients of stem cell transplantation will be included, with the preparative cytoreductive and high-dose therapies counted collectively as one prior therapy.
- •Must be off all cytotoxic chemotherapy for at least four weeks prior to registration for protocol therapy (6 weeks for BCNU or mitomycin C).
- •Patients are allowed to have received one course of prior radioimmunotherapy (RIT: either tositumomab or ibritumomab). NOTE: Radioimmunotherapy must be completed at least 12 weeks prior to registration for protocol therapy with recovery to baseline of ANC and platelets.
- •Prior fludarabine, Velcade or rituximab is allowed as long as therapy is completed at least 30 days prior to registration for protocol therapy. Patients may be refractory (defined as not responding or demonstrating progressive disease in <6 months) to prior rituximab. Patients may not be refractory to prior fludarabine or Velcade.
- •Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed and for 30 days following protocol therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to prior to registration for protocol therapy. NOTE: Patients are considered of child bearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal (no menses for at least 12 months).
- •Females must not be breastfeeding.
- •Males must agree to use an acceptable method of contraception for the duration of the study.
Exclusion Criteria
- •No current active CNS metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis within 7 days prior to registration for protocol therapy. NOTE: Patients with treated brain metastasis must be off steroids or on tapering or stable doses of steroids and have completed radiation at least 30 days prior to registration for protocol therapy.
- •No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason ≤ grade 6 prostate cancers, or other cancer for which the subject has been disease-free for at least 3 years.
- •No treatment with any investigational agent within 30 days prior to registration for protocol therapy.
- •Prior radiation therapy is allowed to < 25% of the bone marrow. NOTE: No radiation therapy within 30 days prior to registration for protocol therapy.
- •No clinically significant infections as judged by the treating investigator.
- •No active HIV, hepatitis B or hepatitic C infection.
- •No cerebrovascular accident (CVA) within 6 months of study enrollment.
- •No psychiatric illness/social situations that would limit compliance with study requirements.
- •No history of hypersensitivity to Velcade, boron or mannitol.
- •No peripheral neuropathy grade > 1.
Arms & Interventions
Fludarabine, Velcade and Rituximab
Experimental
Fludarabine, Velcade and Rituximab
Intervention: Fludarabine (Drug)
Fludarabine, Velcade and Rituximab
Experimental
Fludarabine, Velcade and Rituximab
Intervention: Velcade (Drug)
Fludarabine, Velcade and Rituximab
Experimental
Fludarabine, Velcade and Rituximab
Intervention: Rituximab (Drug)
Outcomes
Primary Outcomes
Overall Response Rate
Time Frame: 6 months
To determine the overall response rate and frequency of complete and partial responses in patients with relapsed or refractory follicular non-Hodgkin lymphoma (NHL) who receive therapy with fludarabine, Velcade, and rituximab administered every 28 days.
Secondary Outcomes
- Survival(6 months)
- Toxicity(6 months)
- Biologic Interaction(6 months)
Investigators
Study Sites (11)
Loading locations...
Similar Trials
Completed
Phase 1
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00536341SCRI Development Innovations, LLC64
Completed
Phase 2
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's LymphomaLymphoma, Non-HodgkinMALT LymphomaNCT00117156Dana-Farber Cancer Institute26
Unknown
Phase 2
Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)T-Cell LymphomasChemotherapyNCT00840385Fudan University30
Completed
Phase 2
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaB-cell Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaNCT00098670National Cancer Institute (NCI)102
Completed
Phase 2
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 YearsChronic Lymphocytic LeukemiaNCT00254410M.D. Anderson Cancer Center30